{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia4dvm6k7dof6cgfrsx7njkurv4zv7hj2iebideaqhaux3yi5ig5q",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mhrvz3aijcy2"
  },
  "path": "/2026/03/24/prestige-biopharma-announces-positive-topline-results-from-comparative-samson-ii-study-for-hd204-a-potential-biosimilar-to-avastin-bevacizumab/",
  "publishedAt": "2026-03-24T03:32:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer SINGAPORE, March 24, 2026 /PRNewswire/ — Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin® (bevacizumab) in adult patients with advanced non-squamous non-small […]",
  "title": "Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)"
}